Trials / Terminated
TerminatedNCT00079859
Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy
Safety and Efficacy Study of Implitapide Compared With Placebo in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (planned)
- Sponsor
- Medical Research Laboratories International · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if implitapide, used in conjunction with other lipid-lowering therapies, is safe and effective when compared to placebo in lowering low-density lipoprotein cholesterol (LDL-C) in patients with heterozygous familial hypercholesterolemia (HeFH).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Implitapide |
Timeline
- Start date
- 2003-10-01
- Completion
- 2005-04-01
- First posted
- 2004-03-18
- Last updated
- 2005-06-24
Locations
6 sites across 3 countries: United States, Netherlands, Norway
Source: ClinicalTrials.gov record NCT00079859. Inclusion in this directory is not an endorsement.